Clinical-Browse

Result: 21 - 40 of 96

DownLoad :

FASTA

HTML

XLS

XML

DRAMP ID	NAME	Description	Medical_use	Stage of development	Company
DRAMP18079	Mersacidin(M87-1551)	Mersacidin is a type-B lantibiotic containing 3-methyllanthionine and S-(2-aminovinyl)-3-methylcysteine residues and four intra-chain thioether bridges. It is obtained from Bacillus sp. HIL Y-85,54728 and is active in vivo against methicillin-resistant Staphylococcus aureus (MRSA). It has a role as a metabolite and an antibacterial agent. It is a type B lantibiotic and a macrocycle. It is a tautomer of a mersacidin zwitterion.	Gram-positive infections,MRSA	Preclinical	Novacta Biosystems Ltd.(Hatfield, England)
DRAMP18080	Plectasin	fungal defensin	Systemic antiâ€“Gram positive,especially pneumococcal and streptococcal infections	Phase I	Novozymes A/S(Bagsvaerd, Denmark)
DRAMP18081	PAC113	based on the active segment of histatin 5 protein found in human saliva	Oral candidiasis in HIV seropositive patients	Phase IIb	Pacgen(Vancouver, BC, Canada)
DRAMP18082	Peptidomimetics	derived from the arylamide, calixarene, hydrazide and salicylamide series	Anti-infectives; antimicrobial polymers and coating materials	Preclinical	Polymedix(Philadelphia)
DRAMP18083	CZEN-002(Melantropin, (CKPV)2)	CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal infections in individuals with compromised immune systems such as those suffering from HIV/AIDS or undergoing organ or bone transplants. The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.	GPB, GNP, Candida. Yeast regulatory mechanisms, Interference by cAMP induction, anti-inflammatory.	Phase IIb	Zengen(Woodland Hills, CA, USA)
DRAMP18084	Talactoferrin alpha(Lactoferroxin-A)	Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.	Combined with chemotherapy in the first-line treatment of advanced non-small cell lung cancer;Topical treatment in diabetic neutropathic ulcers	Phase III	Agennix
DRAMP18085	CSA(cationic steroid antibiotics)	The CSAs share structural features in common with the AMPs that form part of the bodys innate immune system.	Anti-infective,including multi-drug resistant organisms such as pseudomonas, MRSA and vancomycin-resistant S. aureus	Preclinical	Ceragenix
DRAMP18086	Telavancin(TD-6424)	Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.	Osteomyelitis, Bacterial infections (I)	In market	Clinigen Group plc/Innoviva Inc./Pendopharm/Theravance Biopharma Inc./University of Illinois
DRAMP18087	D2A21(Demegal, Provena)	a 22-residue αhelix peptide	Burn infection, skin infection with multidrug-resistant pathogens	Phase III	Demegen
DRAMP18088	EA-230	Oligopeptide fragment fromb-hCG(4-mer, LQGV)	Anti-inflammatory. Sepsis and renal failure protection.	Phase II	Exponential Biotherapies
DRAMP18089	Amphiphilic arylamide polymers	No more description	Anti-infective drug and antimicrobial polymers and coating materials	Preclinical	Polymedix
DRAMP18090	LL-37(Cathelicidin, ropocamptide, Bac4, CAS001)	Human (neutrophils and epithelial cells)	Hard-to-heal venous leg ulcers	Phase I/II	Inimex Pharmaceuticals
DRAMP18091	PTX001	potent anti-angiogenic agents	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18092	PTX002	33-mer peptide;	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18093	PTX004	potent anti-angiogenic agents	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18094	PTX005	12-mer peptide	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18095	PTX006	N-acylated analog of PTX005	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18096	PTX007	a nonpeptidic structural analog of PTX005	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18150	PTX008	potent anti-angiogenic agents	Broad-spectrum antimicrobial;Antiendotoxin	Preclinical	PepTx
DRAMP18151	Glutoxim(NOV-002)	Glutathione Disulfide NOV-002 is a stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and immunomodulating activities. Mimicking endogenous GSSG, glutathione disulfide NOV-002 acts as a competitive substrate for gamma-glutamyl-transpeptidase (GGT), which may result in the S-glutathionylation of proteins, predominantly actin, a redox stress on endoplasmic reticulum (ER), and ER stress-induced apoptosis; S-glutathionylation may be stimulated by reactive oxygen species (ROS) liberated by a glutathione disulfide NOV-002-induced increase in GGT activity. Glutathione disulfide NOV-002 may also induce phosphorylation of proteins such as ERK and p38, two kinases that play critical regulatory roles in cell proliferation and apoptosis. The cisplatin component of this agent does not provide an effective therapeutic concentration of cisplatin in vivo.	Tuberculosis, non small cell, lung cancer	Phase III	Pharma BAM/Novelos